STOCK TITAN

Atrium Therapeutics (RNA) Stock Price, News & Analysis

RNA NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
19 183 sessions, February 27, 2026 to November 17, 2026
Largest daily move
-20% close of September 8, 2026
1-month change
-15.5% closing prices, October 16, 2026 to November 17, 2026

Company Description

Avidity Biosciences, Inc. (Nasdaq: RNA) is a biopharmaceutical company focused on developing a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™). According to the company, its mission is to profoundly improve people's lives by delivering AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases that have been difficult to reach with existing RNA therapies. Avidity is headquartered in San Diego, California and operates in the pharmaceutical preparation manufacturing segment of the broader manufacturing sector.

Avidity states that it has demonstrated the first-ever successful targeted delivery of RNA into muscle using its proprietary AOC platform. Building on this platform, the company is advancing multiple clinical development programs in rare neuromuscular diseases, specifically myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). These diseases are characterized by progressive muscle weakness and significant functional impairment, and in some cases, a lack of approved treatments. Avidity’s work is positioned around addressing the high unmet medical need in these indications.

Core AOC Platform and Therapeutic Focus

The company describes its AOCs as molecules that bring together monoclonal antibodies and oligonucleotide therapies. The monoclonal antibody component is designed to provide target specificity, while the oligonucleotide component is intended to modulate RNA inside cells. By linking these two elements, Avidity aims to deliver RNA-targeting therapies directly to tissues such as skeletal and cardiac muscle. This approach is central to its programs in rare muscle diseases and to its broader pipeline in cardiology and immunology through internal discovery and partnerships.

Avidity’s clinical-stage neuromuscular portfolio includes three named AOC programs that the company has highlighted in its public communications:

  • Delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44).
  • Delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1).
  • Delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD).

According to company disclosures, all three programs are in late-stage clinical development. Avidity reports that it has generated what it describes as groundbreaking or unprecedented data across these neuromuscular programs, including reversal of disease progression and improvements across multiple functional measures in people living with DMD44 treated with del-zota in the EXPLORE44® and EXPLORE44-OLE™ trials. The company also notes that its DM1 program has advanced into a global Phase 3 study (HARBOR™), and that it has initiated a global, confirmatory Phase 3 study (FORTITUDE-3™) intended to support a global approval strategy for del-brax in FSHD.

Lead Program: Del-zota in Duchenne Muscular Dystrophy (DMD44)

Duchenne muscular dystrophy is described by Avidity as a monogenic, X-linked, recessive disease that primarily affects males and is characterized by a lack of functional dystrophin. This lack of dystrophin leads to stress and tears of muscle cell membranes, muscle cell death, and progressive loss of muscle function. People living with DMD typically experience early-onset progressive muscle weakness, eventually developing problems walking and breathing, with heart and respiratory muscles ultimately affected. While there are approved treatments for DMD, the company notes that there remains a very high unmet need, and that there are no approved exon 44 skipping therapies for DMD44.

Del-zota is described as an investigational AOC designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene, with the goal of enabling dystrophin production in people with DMD44. The molecule consists of a proprietary monoclonal antibody that binds to transferrin receptor 1 (TfR1) conjugated to a PMO targeting exon 44. In the Phase 1/2 EXPLORE44 trial and the EXPLORE44-OLE™ extension, Avidity reports that del-zota achieved what it characterizes as unsurpassed delivery of PMOs to skeletal muscle, robust increases in dystrophin production, significant increases in exon 44 skipping, and significant and sustained decreases of creatine kinase levels to near normal.

Functional data disclosed by the company indicate that participants treated with del-zota showed improvements compared to DMD natural history across several measures, including Time to Rise from Floor (TTR), 4-Stair Climb (4SC), Performance of Upper Limb (PUL) and the 10-Meter Walk/Run Test (10mWRT). Avidity also reports that del-zota continued to demonstrate a favorable long-term safety and tolerability profile, with most treatment-emergent adverse events described as mild or moderate, and one discontinuation due to hypersensitivity.

The company has announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to del-zota for DMD44. Following a pre-Biologics License Application (BLA) meeting, Avidity has stated that it aligned with the FDA on a path forward for a BLA submission for del-zota, with the timing updated to the first quarter of 2026 to provide additional data to support the chemistry, manufacturing, and controls package. The company has also described plans for a confirmatory study to support full global approval of del-zota.

Del-desiran in Myotonic Dystrophy Type 1 (DM1)

Myotonic dystrophy type 1 is described as an underrecognized, progressive and often fatal disease caused by a triplet-repeat in the DMPK gene, resulting in a toxic gain-of-function mRNA. Avidity notes that DM1 is highly variable in severity, presentation and age of onset, but that all forms are associated with high disease burden and may cause premature mortality. The disease primarily affects skeletal and cardiac muscle, and can involve myotonia, muscle weakness, respiratory problems, fatigue, hypersomnia, cardiac abnormalities, gastrointestinal complications, and cognitive and behavioral impairment. The company states that there are no approved treatments for people living with DM1.

Del-desiran is Avidity’s AOC candidate for DM1. The company reports that it has advanced del-desiran into the global Phase 3 HARBOR™ trial, which it describes as the first global Phase 3 trial of this agent for DM1. Avidity has also referenced earlier-stage data from the Phase 1/2 MARINA® trial and has indicated plans for data analyses and readouts from HARBOR™. These disclosures position del-desiran as a key part of Avidity’s late-stage neuromuscular pipeline.

Del-brax in Facioscapulohumeral Muscular Dystrophy (FSHD)

Facioscapulohumeral muscular dystrophy is described as a rare, progressive, and variable hereditary muscle-weakening condition marked by pain, fatigue, disability and progressive skeletal muscle loss. It typically begins with weakness in muscles of the face, shoulders, arms and trunk, and can progress to the lower body, often leading to wheelchair dependence. FSHD is attributed to aberrant expression of the DUX4 gene in skeletal muscle, which activates genes that are toxic to muscle cells and leads to muscle wasting and compromised function. Avidity notes that there are currently no approved treatments for people living with FSHD.

Del-brax is Avidity’s AOC candidate for FSHD. The company has described topline data expectations from the FORTITUDE™ biomarker cohort and has indicated that it has aligned with the FDA on accelerated and full approval pathways for del-brax. Avidity has also reported initiation of the global, confirmatory Phase 3 FORTITUDE-3™ study, which is intended to support a global approval strategy for del-brax.

Broader Pipeline: Cardiology and Immunology

Beyond neuromuscular diseases, Avidity reports that it is advancing two wholly owned precision cardiology development candidates that address rare genetic cardiomyopathies. The company has identified programs targeting phospholamban (PLN) and Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome as part of its early-stage precision cardiology efforts, which are expected to be separated into a new public company (SpinCo) in connection with the proposed acquisition by Novartis AG.

Avidity also states that it is broadening the reach of AOCs with an advancing and expanding pipeline that includes programs in cardiology and immunology through key partnerships. The company has disclosed collaboration and license agreements with partners such as Eli Lilly and Company and Bristol Myers Squibb, and has reported collaboration revenues and milestones associated with these arrangements.

Planned Acquisition by Novartis and Spin-Off of Precision Cardiology Programs

Avidity has entered into an Agreement and Plan of Merger with Novartis AG and an indirect wholly owned Novartis subsidiary. Under this agreement, the subsidiary is expected to merge with and into Avidity, with Avidity surviving as an indirect wholly owned subsidiary of Novartis, subject to customary closing conditions. In connection with the merger, Avidity has also entered into a Separation and Distribution Agreement providing for a pre-closing reorganization in which a newly formed subsidiary (SpinCo) will own assets and liabilities related to early-stage precision cardiology programs and certain collaboration agreements.

Following this reorganization, Avidity has disclosed that SpinCo is expected either to be distributed to Avidity stockholders on a pro rata basis (the Spin-Off Distribution) or to be sold to a third party, subject to the terms of the merger agreements. Novartis is expected to acquire Avidity’s programs and pipeline in neuroscience and to gain access to its RNA-targeting delivery platform, including the late-stage neuromuscular programs del-zota, del-desiran and del-brax. The companies have stated that they expect the transactions to close in the first half of 2026, subject to completion of the SpinCo separation, regulatory approvals, stockholder approval and other customary conditions.

Regulatory filings indicate that the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the transactions, satisfying one of the conditions to closing. Other conditions, including completion of the SpinCo separation and stockholder approval, remain to be satisfied or waived before the merger can be consummated.

Advocacy Engagement and Patient Community Focus

Avidity emphasizes engagement with patient and advocacy communities, particularly in the context of neuromuscular and rare diseases. During National Muscular Dystrophy Awareness Month, the company has described activities such as supporting World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, the FSHD Society Walk & Roll to Cure FSHD, and Global Genes Week in RARE. It has also referenced participation in events organized by groups such as the Jett Foundation and Defeat Duchenne Canada, reflecting an emphasis on collaboration with patient organizations and awareness initiatives.

Stock Listing and Regulatory Filings

Avidity’s common stock, with a par value of $0.0001 per share, is listed on The Nasdaq Global Market under the trading symbol RNA. The company files periodic and current reports, including Forms 8-K, with the U.S. Securities and Exchange Commission (SEC). These filings cover topics such as clinical data updates, regulatory designations, public offerings of common stock, collaboration milestones, and details of the proposed merger and SpinCo separation. Investors and analysts use these filings to track material events, transaction terms, and developments in Avidity’s clinical and corporate strategy.

Stock Performance

$6.48
+0.78%
+0.05
Last updated: at
-15.5%
Performance 1 month
$139.8M

Atrium Therapeutics (RNA) closed at $6.48 on November 17, 2026. Over the past month, the price has lost 15.5%.

See what a $1,000 investment in RNA would be worth today

Average down calculator for RNA

RNA Metrics & Rankings

Price returns through November 17, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Atrium Therapeutics has 10 recent news articles, with the latest published on . Of the recent coverage, 9 articles coincided with positive price movement and 1 with negative movement. Key topics include earnings, clinical trial, private placement, conferences. View all RNA news →

Financial Highlights

Atrium Therapeutics has not filed a full fiscal year of results yet, so there are no annual figures to show here, and the quarterly figures it has reported so far are on its financials page.

Upcoming Events

H2
2026
H2 2026 Clinical

First patient enrollment

First patient enrollment in Corventis Phase 1/2 trial across multicenter U.S. sites for ATR-1072 in PRKAG2 syndrome.
YEAR
2027
2027 Regulatory

ATR 1086 IND filing

ATR 1086 IND targeted in 2027; CMC planned to support IND-enabling
YEAR
2027
2027 Regulatory

IND planned ATR-1086

Plans IND filing for ATR-1086 in 2027; potential clinical program initiation; monitor regulatory submissions and updates.
YEAR
2027
2027 Product

Candidate selection

Atrium expects to select another development candidate in 2027; decision will shape pipeline priorities and R&D plans.
APR
20
April 20, 2027 Corporate

25% vesting of inducement awards

25% vesting of 101,250 options and 50,625 RSUs granted 2026-04-20; options strike $14.30; subject to continued service.
H2
2027
H2 2027 Clinical

Corventis trial data

Atrium expects initial proof-of-concept data from the Phase 1/2 Corventis trial in H2 2027; topline clinical readout window.
H2
2027
H2 2027 Clinical

Initial proof-of-concept data

Atrium's Phase 1/2 Corventis trial (ATR 1072) initial proof-of-concept data expected in H2 2027; ~37 global participants.
H2
2027
H2 2027 Clinical

Proof-of-concept data

Initial proof-of-concept data from Corventis Phase 1/2 expected in H2 2027 assessing cardiac structure, function and PK/PD.
SEP
20
September 20, 2027 Corporate

First vesting date

25% of options (13,500 shares) and RSUs (6,750 shares) vest for a newly hired employee; subject to continued service.
SEP
20
September 20, 2030 Corporate

Final vesting completion

Remaining options vest monthly over 36 months and RSUs vest via three annual installments; final vesting completes on this date.

Atrium Therapeutics has 10 upcoming scheduled events. The next event, "First patient enrollment", is expected in H2 2026. Investors can track these dates to stay informed about potential catalysts that may affect the RNA stock price.

Short Interest History

Last 12 Months

Short interest in Atrium Therapeutics (RNA) currently stands at 3.7 million shares, up 0.6% from the previous reporting period, representing 17.8% of the float. Since February 2026, short interest has increased by 766.3%.

Days to Cover History

Last 12 Months

Days to cover for Atrium Therapeutics (RNA) currently stands at 16.1 days, up 24.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since February 2026, the figure has increased by 1507%. Across the settlements charted above, it has ranged from 1.0 to 28.4 days.

RNA Company Profile & Sector Positioning

Atrium Therapeutics (RNA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing RNA often look at related companies in the same sector, including Sutro Biopharma, Inc. (STRO), Zentalis Pharmaceuticals, Inc. (ZNTL), enGene Therapeutics Inc. (ENGN), Fate Therapeutics, Inc. (FATE), and Korro Bio, Inc. (KRRO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RNA's relative position within its industry.

Frequently Asked Questions

The current stock price of Atrium Therapeutics (RNA) is $6.48 as of November 17, 2026.

The market cap of Atrium Therapeutics (RNA) is approximately $139.8M. Learn more about what market capitalization means .

Avidity Biosciences focuses on developing Antibody Oligonucleotide Conjugates (AOCs™), a class of RNA therapeutics that link monoclonal antibodies with oligonucleotide therapies. The company applies this platform primarily to rare muscle diseases such as myotonic dystrophy type 1, Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy, and is also advancing precision cardiology and other programs.

According to Avidity, Antibody Oligonucleotide Conjugates (AOCs™) are molecules that combine the target specificity of monoclonal antibodies with the RNA-modulating capabilities of oligonucleotide therapies. This design is intended to enable targeted delivery of RNA therapeutics to specific tissues, such as muscle, and to address diseases that have been difficult to reach with existing RNA therapies.

Avidity highlights three late-stage neuromuscular programs as central to its pipeline: delpacibart etedesiran (del-desiran) for myotonic dystrophy type 1 (DM1), delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy with mutations amenable to exon 44 skipping (DMD44), and delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD).

Avidity’s approach to Duchenne muscular dystrophy involves delpacibart zotadirsen (del-zota), an investigational AOC designed to deliver phosphorodiamidate morpholino oligomers to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene. The company reports that del-zota has shown increases in dystrophin production, significant exon 44 skipping, and improvements in functional measures in people living with DMD44 in clinical trials.

Yes. Avidity has disclosed that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to delpacibart zotadirsen (del-zota) for the treatment of Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping (DMD44).

The HARBOR™ trial is a global Phase 3 study of delpacibart etedesiran (del-desiran) in people living with myotonic dystrophy type 1. Avidity has described it as the first global Phase 3 trial of del-desiran for DM1, making it a key component of the company’s strategy to generate data that could support potential regulatory submissions in this indication.

Avidity is developing delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy, a hereditary muscle-weakening condition linked to aberrant expression of the DUX4 gene. The company has initiated the global Phase 3 FORTITUDE-3™ study and has indicated that this trial is intended to support a global approval strategy for del-brax.

Avidity reports that it is advancing two wholly owned precision cardiology development candidates that address rare genetic cardiomyopathies, including programs targeting phospholamban (PLN) and PRKAG2 syndrome. These early-stage cardiology programs are part of the company’s broader effort to extend its AOC platform beyond neuromuscular diseases.

SpinCo is the name used in Avidity’s transaction documents for a newly formed subsidiary that will hold assets and liabilities related to early-stage precision cardiology programs and certain collaboration agreements. In connection with a planned acquisition of Avidity by Novartis AG, SpinCo is expected either to be distributed to Avidity stockholders or sold to a third party before the merger closes.

Avidity has entered into a definitive merger agreement with Novartis AG under which an indirect wholly owned Novartis subsidiary will merge with and into Avidity, with Avidity surviving as an indirect wholly owned subsidiary of Novartis. The closing of this acquisition is subject to conditions including completion of the SpinCo separation, regulatory approvals, and approval by Avidity’s stockholders, and is expected by the parties to occur in the first half of 2026 based on current disclosures.

Avidity Biosciences is headquartered in San Diego, California. Its common stock is listed on The Nasdaq Global Market under the ticker symbol RNA, as indicated in its SEC filings.